Estados financieros detallados de Alaunos Therapeutics, Inc. (TCRT): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $6.9M | $6.4M | $146000 | 0 | 0 | $398000 | $2.9M | $5000 | $10000 | $5000 |
| Coste de Ventas | 0 | 0 | 0 | $629000 | $1.1M | $47.3M | $22.5M | $4.8M | $362000 | $1.4M |
| Beneficio Bruto | $6.9M | $6.4M | $146000 | -$629000 | -$1.1M | -$46.9M | -$19.6M | -$4.8M | -$352000 | -$1.4M |
| I+D | $157.8M | $45.1M | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $362000 | $1.4M |
| Generales y Administrativos | $14.4M | $14.8M | $19.9M | $18.9M | $26.5M | $26.3M | $13.1M | $12.2M | $4.5M | $2.9M |
| Gastos Operativos | $172.2M | $59.9M | $54.1M | $57.2M | $79.2M | $30.7M | $15.5M | $29.5M | $4.5M | $2.9M |
| Beneficio Operativo | -$165.3M | -$53.5M | -$53.9M | -$57.9M | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.8M | -$4.2M |
| EBITDA | -$165.0M | -$53.1M | -$53.3M | -$117.2M | -$78.8M | -$75.0M | -$31.8M | -$30.9M | -$4.7M | -$4.2M |
| Gastos por Intereses | 0 | $830000 | 0 | 0 | 0 | $1.2M | $3.2M | $1.9M | 0 | 0 |
| Beneficio Antes de Impuestos | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| Impuestos | $114000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| BPA | $-190.15 | $-59.50 | $-55.52 | $-158.90 | $-56.42 | $-53.80 | $-25.97 | $-21.97 | $-2.92 | $-2.20 |
| BPA Diluido | $-190.15 | $-59.50 | $-55.44 | $-158.90 | $-56.42 | $-53.80 | $-25.97 | $-21.97 | $-2.92 | $-2.20 |
| Acciones en Circulación (Diluidas) | $869276 | $912921 | $956724 | $1.1M | $1.4M | $1.4M | $1.4M | $1.6M | $1.6M | $1.9M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | $3000 | 0 | 0 |
| Beneficio Bruto | -$469000 | -$358000 | -$8000 | -$9000 |
| Beneficio Operativo | -$1.2M | -$907000 | -$1.0M | -$952000 |
| EBITDA | -$1.2M | -$886000 | -$998000 | -$943000 |
| Beneficio Neto | -$1.2M | -$893000 | -$1.0M | -$952000 |
| BPA | $-0.55 | $-0.40 | $-0.59 | $-0.41 |
| BPA Diluido | $-0.55 | $-0.40 | $-0.59 | $-0.41 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $81.1M | $70.9M | $61.7M | $79.7M | $115.1M | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $21000 | $19000 | $1.9M | $3.3M | $4.7M | $1.1M | $4000 | $1000 | $5000 | $3000 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | $13.9M | 0 | 0 | 0 |
| Activos Corrientes | $104.9M | $90.8M | $84.3M | $105.5M | $130.6M | $78.8M | $53.8M | $8.3M | $2.8M | $2.0M |
| Inmovilizado Material | $843000 | $1.2M | $1.1M | $3.4M | $14.9M | $15.4M | $10.6M | $2000 | 0 | $91000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $106.3M | $105.6M | $95.1M | $109.1M | $146.3M | $94.9M | $64.9M | $8.3M | $2.8M | $3.0M |
| Cuentas por Pagar | $156000 | $4.4M | $707000 | $906000 | $960000 | $1.4M | $1.4M | $616000 | $516000 | $613000 |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | $8.6M | $17.3M | 0 | 0 | 0 |
| Pasivos Corrientes | $15.8M | $20.9M | $9.5M | $12.5M | $18.4M | $16.0M | $24.2M | $2.0M | $692000 | $813000 |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | $16.2M | 0 | 0 | 0 | 0 |
| Pasivos Totales | $183.6M | $202.4M | $9.5M | $14.1M | $22.4M | $36.8M | $26.4M | $2.0M | $692000 | $813000 |
| Reservas | -$658.0M | -$712.4M | -$566.3M | -$684.1M | -$764.1M | -$842.9M | -$880.6M | -$915.8M | -$920.4M | -$924.6M |
| Patrimonio Neto | -$77.3M | -$96.8M | $85.6M | $95.0M | $124.0M | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M |
| Deuda Total | 0 | 0 | 0 | $2.4M | $4.8M | $30.1M | $20.1M | 0 | 0 | 0 |
| Deuda Neta | -$81.1M | -$70.9M | -$61.7M | -$77.4M | -$110.3M | -$46.0M | -$19.0M | -$6.1M | -$1.1M | -$1.4M |
| Capital Circulante | $89.1M | $69.9M | $74.8M | $93.0M | $112.2M | $62.8M | $29.6M | $6.3M | $2.1M | $1.2M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $1.9M | $1.4M | $354000 | $124000 |
| Activos Totales | $3.7M | $3.0M | $1.9M | $1.5M |
| Pasivos Totales | $921000 | $813000 | $595000 | $864000 |
| Patrimonio Neto | $2.8M | $2.2M | $1.3M | $652000 |
| Deuda Total | 0 | 0 | 0 | 0 |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| Amortizaciones | $290000 | $369000 | $575000 | $629000 | $1.1M | $2.6M | $2.8M | $2.3M | $2000 | $7000 |
| Compensación en Acciones | $8.5M | $8.5M | $7.5M | $7.3M | $6.8M | $10.8M | $3.5M | $2.8M | $435000 | $414000 |
| Cambio en Capital Circulante | -$20.9M | -$10.5M | -$4.3M | $8.2M | $15.0M | $3.1M | $870000 | -$6.3M | -$729000 | $473000 |
| Flujo de Caja Operativo | -$58.3M | -$54.7M | -$49.5M | -$40.9M | -$57.0M | -$61.5M | -$29.2M | -$30.1M | -$5.0M | -$2.9M |
| Inversiones (CapEx) | -$551000 | -$737000 | -$459000 | -$284000 | -$9.8M | -$3.3M | -$216000 | -$197000 | 0 | -$98000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | -$1.5M | -$2.1M | -$1.6M | -$653000 | 0 | 0 | -$45000 | 0 | 0 | 0 |
| Dividendos Pagados | -$7.1M | 0 | -$17.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$58.9M | -$55.4M | -$49.9M | -$41.1M | -$66.8M | -$64.8M | -$29.4M | -$30.3M | -$5.0M | -$3.0M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$844000 | -$552000 | -$1.0M | -$300000 |
| Inversiones (CapEx) | -$97000 | -$1000 | 0 | 0 |
| Flujo de Caja Libre | -$941000 | -$553000 | -$1.0M | -$300000 |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $127000 | $35000 | $56000 | $57000 |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | -6.9% | -97.7% | -100.0% | | | +634.2% | -99.8% | +100.0% | -50.0% |
| Crecimiento Beneficio Neto (anual) | | +67.1% | +2.2% | -121.8% | +32.1% | +1.5% | +52.1% | +6.9% | +86.7% | +10.8% |
| Crecimiento BPA (anual) | | +68.7% | +6.7% | -186.2% | +64.5% | +4.6% | +51.7% | +15.4% | +86.7% | +24.7% |
| Cambio en Acciones (anual) | | +5.0% | +4.8% | +17.0% | +24.8% | +2.3% | +1.3% | +10.5% | +0.1% | +21.7% |
| Crecimiento FCF (anual) | | +5.9% | +9.9% | +17.6% | -62.4% | +3.0% | +54.5% | -3.0% | +83.6% | +40.3% |
| Margen Bruto | 100.0% | 100.0% | 100.0% | | | -11778.1% | -670.6% | -95960.0% | -3520.0% | -27160.0% |
| Margen Operativo | -2409.4% | -837.3% | -36921.9% | | | -19484.7% | -1201.4% | -685340.0% | -48120.0% | -84500.0% |
| Margen EBITDA | -2405.0% | -831.5% | -36528.1% | | | -18835.4% | -1088.9% | -618080.0% | -46770.0% | -83380.0% |
| Margen Neto | -2409.2% | -850.3% | -36381.5% | | | -19786.7% | -1291.2% | -702800.0% | -46790.0% | -83520.0% |
| Margen FCF | -858.1% | -867.2% | -34189.0% | | | -16279.1% | -1007.8% | -606780.0% | -49710.0% | -59340.0% |
| Tasa Impositiva Efectiva | -0.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-67.73 | $-60.69 | $-52.17 | $-36.74 | $-47.79 | $-45.33 | $-20.34 | $-18.97 | $-3.10 | $-1.52 |
| Dividendo por Acción | $8.19 | $0.00 | $17.77 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $869276 | $912921 | $956724 | $1.1M | $1.4M | $1.4M | $1.4M | $1.6M | $1.6M | $1.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Salud financiera
| Piotroski F-Score | 2 |
| Altman Z-Score | -436.02 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -4.22 | -10.44 | -5.05 | -4.46 | -6.70 | -3.04 | -3.75 | -0.48 | -0.65 | -1.47 |
| P/VC | -9.02 | -5.86 | 3.14 | 8.34 | 4.26 | 4.03 | 3.66 | 2.69 | 1.48 | 2.92 |
| P/V | 101.68 | 88.73 | 1838.09 | 0.00 | 0.00 | 587.17 | 48.24 | 3394.19 | 305.84 | 1258.64 |
| Margen Bruto | 100.0% | 100.0% | 100.0% | 0.0% | 0.0% | -11778.1% | -670.6% | -95960.0% | -3520.0% | -27160.0% |
| Margen Operativo | -2409.4% | -837.3% | -36921.9% | 0.0% | 0.0% | -19484.7% | -1201.4% | -685340.0% | -48120.0% | -84500.0% |
| Margen Neto | -2409.2% | -850.3% | -36381.5% | 0.0% | 0.0% | -19786.7% | -1291.2% | -702800.0% | -46790.0% | -83520.0% |